GSK plc 6-K, filed Sep 6, 2022
GSK plc (GSK)
6-K
2022-09-06
For: 2022-09-06
View Original
Added on
April 10, 2026
About this 6-K
GSK plc filed this 6-K on September 6, 2022.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of September 2022
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
Issued: 6 September 2022, London UK
GSK announces update on US FDA regulatory review of daprodustat in
anaemia of chronic kidney disease
GSK plc (LSE/NYSE: GSK) today announced that the
US Food and Drug Administration (FDA) will convene a meeting of the
Cardiovascular and Renal Drugs Advisory Committee to review the New
Drug Application (NDA) for daprodustat, an oral hypoxia-inducible
factor prolyl hydroxylase inhibitor (HIF-PHI) under regulatory
review for the potential treatment of anaemia
due to chronic kidney disease (CKD) in adult patients on dialysis
and not on dialysis.
GSK is committed to working closely with the US FDA to bring
daprodustat to appropriate patients with anaemia of CKD. A date for
the Advisory Committee meeting is set for 26 October
2022.
Chris Corsico, Senior Vice President, Development, GSK
said: "We
believe daprodustat and the results demonstrated in the ASCEND
clinical trial programme have significant potential for patients
living with anaemia of CKD who currently do not have an oral
treatment option. We look forward to participating in the upcoming
Advisory Committee meeting and working with the US FDA to complete
its assessment of daprodustat, with the goal of bringing this
innovative new treatment to appropriate patients in the
US."
The daprodustat NDA is based on positive results from the ASCEND
phase III clinical trial programme, which included five
pivotal studies
assessing the efficacy and safety of daprodustat for the treatment
of anaemia across the spectrum of CKD. Results from the key
cardiovascular outcomes studies were published in
the New England
Journal of Medicine in November 2021 and
included non-dialysis (ASCEND-ND)
and dialysis (ASCEND-D)
CKD patients. These studies demonstrated that daprodustat improved
and/or maintained haemoglobin (Hb) within
the target level (10-11.5 g/dL), and
the primary safety analysis of the intention-to-treat (ITT)
populations showed that daprodustat achieved non-inferiority of
MACE (major adverse cardiovascular events) compared to the standard
of care, an erythropoietin stimulating agent (ESA), across both
non-dialysis and dialysis patient settings.
In March
2022, the
European Medicines Agency validated the marketing authorisation
application for daprodustat, which is currently under regulatory
review. Additional regulatory submissions are anticipated to
continue throughout 2022. In June 2022, Duvroq (daprodustat)
tablets were approved by Japan's Ministry of Health, Labour and
Welfare for patients with renal anaemia.
About the ASCEND phase III clinical trial programme
The ASCEND programme includes five phase III studies to assess the
efficacy and safety profile of daprodustat for the treatment of
anaemia of CKD across the disease spectrum. The programme enrolled
over 8,000 patients who were treated for up to 4.26 years. Results
from all five studies were presented at the American Society of
Nephrology's Kidney Week 2021.
Results from the two pivotal cardiovascular outcomes studies,
ASCEND-ND and ASCEND-D, which investigated patients not on dialysis
and on dialysis, respectively, were also published in
the New England Journal of
Medicine[i],[ii]:
●
ASCEND-ND (Anaemia
Studies in CKD: Erythropoiesis via a Novel PHI
Daprodustat-Non-Dialysis) enrolled 3,872
non-dialysis dependent patients with anaemia of CKD who were either
switched from the standard of care (ESA) or not currently receiving
ESA therapy to receive daprodustat or ESA control (darbepoetin
alfa). Iron management protocols were instituted across both arms
of the study. The study met its primary efficacy and safety
endpoints. Results showed that daprodustat improved and/or
maintained Hb within the target level (10-11.5 g/dL) for these
patients, and the primary safety analysis of the ITT population
showed that daprodustat achieved non-inferiority of MACE compared
to ESA control.
●
ASCEND-D (Anaemia
Studies in CKD: Erythropoiesis via a Novel PHI
Daprodustat-Dialysis) enrolled 2,964 dialysis patients with anaemia
of CKD who were switched to receive daprodustat
or ESA control from a standard of care ESA therapy. A uniform iron
management protocol was instituted across both arms of the study.
The study met its primary efficacy and safety endpoints. Results
showed that daprodustat improved or maintained Hb within target
levels (10-11.5 g/dL) for these patients, and the primary safety
analysis of the ITT population showed that daprodustat achieved
non-inferiority of MACE compared to ESA
control.
About anaemia of chronic kidney disease
CKD, characterised by progressive
loss of kidney function, is an increasing global public health
burden.[iii] Risk
factors for CKD include hypertension, diabetes, obesity and primary
renal disorders.iii Furthermore,
CKD is an independent risk factor for cardiovascular
disease.iii Anaemia
is an important and frequent complication of
CKD.[iv] However,
it is often poorly diagnosed and undertreated in patients with
early-stage CKD, such as those not on dialysis.iv Over
700 million patients suffer from CKD worldwide, and an estimated
one in seven have anaemia.[v],[vi] When
left untreated or undertreated, anaemia of CKD is associated with
poor clinical outcomes and leads to a substantial burden on
patients and healthcare systems.iv
Daprodustat, a HIF-PHI, belongs to a novel class of oral medicines
being studied for the treatment of anaemia of CKD in adult
patients not
on dialysis and on dialysis. Inhibition of oxygen-sensing prolyl
hydroxylase enzymes stabilises hypoxia-inducible factors, which can
lead to transcription of erythropoietin and other genes involved in
the correction of anaemia, similar to the physiological effects
that occur in the human body at high altitude. Daprodustat is being
developed to provide a convenient oral treatment option for
patients with anaemia of CKD.
About GSK
GSK is a global biopharma company with a purpose to unite science,
technology, and talent to get ahead of disease together. Find out
more at gsk.com/company
|
GSK enquiries
|
|
|
|
|
Media:
|
Tim
Foley
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Dan
Smith
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Kathleen
Quinn
|
+1 202
603 5003
|
(Washington
DC)
|
|
|
Lyndsay
Meyer
|
+1 202
302 4595
|
(Washington
DC)
|
|
|
|
|
|
|
Investor
Relations:
|
Nick
Stone
|
+44 (0)
7717 618834
|
(London)
|
|
|
James
Dodwell
|
+44 (0)
20 8047 2406
|
(London)
|
|
|
Mick
Readey
|
+44 (0)
7990 339653
|
(London)
|
|
|
Josh
Williams
|
+44 (0)
7385 415719
|
(London)
|
|
|
Jeff
McLaughlin
|
+1 215
751 7002
|
(Philadelphia)
|
Cautionary statement regarding forward-looking
statements
GSK
cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described in the Company's
Annual Report on Form 20-F for 2021, GSK's Q2 Results for 2022 and
any impacts of the COVID-19 pandemic.
No.
3888792
980
Great West Road
Brentford,
Middlesex
TW8
9GS
[i] Singh
A, et al. Daprodustat for the Treatment of Anemia in Patients Not
Undergoing Dialysis. N Engl J
Med. 2021;
385:2313-2324.
[ii] Singh
A, et al. Daprodustat for the Treatment of Anemia in Patients
Undergoing Dialysis. N Engl J
Med.
2021;385:2325-2335.
[iii]
Hill NR, Fatoba ST, Oke JL, et al. Global prevalence of chronic
kidney disease - A systematic review and
meta-analysis. PLoS
One.
2016;11(7):e0158765.
[iv] St
Peter WL, Guo H, Kabadi S, et al. Prevalence, treatment patterns,
and healthcare resource utilization in Medicare and commercially
insured non-dialysis-dependent chronic kidney disease patients with
and without anemia in the United States. BMC
Nephrol.
2018;19(1):67.
[v] Bikbov
B, Purcell CA, Levey AS, et al. Global, regional, and national
burden of chronic kidney disease, 1990-2017: a systematic analysis
for the Global Burden of Disease Study
2017. Lancet.
2020;395(10225):709-733.
[vi] Stauffer
ME, Fan T. Prevalence of anemia in chronic kidney disease in the
United States. PLoS
One. 2014;9(1):e84943.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: September
06, 2022
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|